Immunic Inc (IMUX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Immunic Inc (IMUX) has a cash flow conversion efficiency ratio of 2.889x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-19.28 Million) by net assets ($-6.67 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Immunic Inc balance sheet independence to measure how much of total assets are equity-financed.
Immunic Inc - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how Immunic Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore Immunic Inc (IMUX) debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
Immunic Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Immunic Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Acme United Corporation
NYSE MKT:ACU
|
-0.019x |
|
Wam Research Ltd
AU:WAX
|
0.017x |
|
Digia Oyj
HE:DIGIA
|
0.083x |
|
Yapi Kredi Koray Gayrimenkul Yatirim Ortakligi AS
IS:KGYO
|
-0.140x |
|
Amaero Ltd
AU:3DA
|
-0.190x |
|
MAX Automation SE
XETRA:MXHN
|
0.111x |
|
Panion & BF Biotech Inc
TW:1760
|
0.039x |
|
Amplify Energy Corp
NYSE:AMPY
|
-0.030x |
Annual Cash Flow Conversion Efficiency for Immunic Inc (2011–2025)
The table below shows the annual cash flow conversion efficiency of Immunic Inc from 2011 to 2025. For the full company profile with market capitalisation and key ratios, see Immunic Inc market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-6.67 Million | $-85.81 Million | 12.859x | +379.56% |
| 2024-12-31 | $18.43 Million | $-84.77 Million | -4.600x | -87.88% |
| 2023-12-31 | $28.93 Million | $-70.83 Million | -2.448x | -327.23% |
| 2022-12-31 | $113.68 Million | $-65.14 Million | -0.573x | +12.49% |
| 2021-12-31 | $127.11 Million | $-83.23 Million | -0.655x | -125.41% |
| 2020-12-31 | $158.78 Million | $-46.12 Million | -0.290x | +40.61% |
| 2019-12-31 | $58.36 Million | $-28.55 Million | -0.489x | +85.92% |
| 2018-12-31 | $12.43 Million | $-43.16 Million | -3.473x | -330.30% |
| 2017-12-31 | $50.04 Million | $-40.40 Million | -0.807x | -31.88% |
| 2016-12-31 | $58.45 Million | $-35.77 Million | -0.612x | -0.88% |
| 2015-12-31 | $82.33 Million | $-49.95 Million | -0.607x | -45.00% |
| 2014-12-31 | $97.56 Million | $-40.83 Million | -0.418x | +39.50% |
| 2013-12-31 | $41.42 Million | $-28.65 Million | -0.692x | -157.11% |
| 2012-12-31 | $-7.63 Million | $-9.24 Million | 1.211x | +748.41% |
| 2011-12-31 | $-54.85 Million | $-7.83 Million | 0.143x | -- |
About Immunic Inc
Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative… Read more